Clinical Trial Update: Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating erlotinib hydrochloride for HIV-infected patients with metastatic or unresectable non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HIV Infection, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Status: TERMINATED